Michigan Dept of Health & Human Services Opioid Settlement Updates - Public Funding Opportunities - July, 2024

MDHHS banner with logo no names

Greetings,

The MDHHS Opioid Policy Team is excited to welcome you to the Michigan Opioid Settlement Updates mailing list.

We would like to share with you a new opioid settlements funded opportunity.

The Recovery Housing Investment Program (RHIP) provides grant funding to expand access to recovery housing for people with opioid use disorder (OUD) and any co-occurring substance use disorder (SUD) or mental health condition(s). The awarded funds will be structured as forgivable loans or grants to purchase or lease single family homes or small multifamily properties for use as recovery housing.

Completed application documents are due to the Michigan State Housing Development Authority (MSHDA) by Friday, July 26, with plans to announce funded applicants no later than Friday, August 16.

Please feel free to contact beaglen1@michigan.gov with any questions.


To better support your work, we would like to share some other funding opportunities that we have been made aware of.*

1. SAMHSA has recently released two funding announcements in collaboration with the Minority AIDS Initiative. Of particular interest for viral hepatitis programs is the: 

2. Foundation for Opioid Response Efforts (FORE) released a Request for Proposals (RFP) for its Opioid Crisis Innovation Challenge 2024. This opportunity seeks to generate new ideas and potential solutions to significant problems that were identified in discussions with experts in the field as impediments to addressing the nation’s opioid and overdose crisis.

  • Applicants may apply for a grant of up to $300,000 a year for up to two years. All applications must be submitted through our grants management system by 11:59 a.m., EST, Thursday, Aug. 8.

 

*The State of Michigan and MDHHS do not operate or have control over these funding opportunities.


We would also like to take this opportunity to share some other important updates with you that we hope can better inform and support you community.

MDHHS is warning Michigan residents about medetomidine, a new drug identified in overdose deaths. 

Medetomidine is a veterinary tranquilizer, similar to xylazine, that can cause adverse effects including slowed heart rate, low blood pressure and decreases in brain and spinal cord activity. It is not approved for use in people.

MDHHS approved eight pre-paid inpatient health plans (PIHPs) to participate in the Recovery Incentives Pilot. This pilot, supported by $6 million in opioid settlement funds over the next three years, will expand access to evidence-based treatment for Medicaid and Healthy Michigan Plan enrollees who are living with certain substance use disorders (SUDs).

You are subscribed to Opioid Settlement Updates - Public for Michigan Dept of Health & Human Services. This information has recently been updated, and is now available.